10x Genomics
TXG
266 hedge funds and large institutions have $2.36B invested in 10x Genomics in 2024 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 104 increasing their positions, 73 reducing their positions, and 49 closing their positions.
209% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $2.06M
42% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 73
16% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 49
15% more capital invested
Capital invested by funds: $2.05B → $2.36B (+$307M)
2% more funds holding
Funds holding: 261 → 266 (+5)
1.64% less ownership
Funds ownership: 99.74% → 98.1% (-1.6%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$50.6M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$29.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.4M |
| 4 |
DM
Deerfield Management
New York
|
+$18.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Generation Investment Management
London,
United Kingdom
|
-$56.1M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$55.9M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$48M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$19.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$11.5M |
TXG Hedge Fund Activity: Q3 2024 in Review
266 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2024, worth a combined $2.36B — up 15% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new TXG positions and 49 closed out — a net gain of 8 holders — while 104 added to existing stakes and 73 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $50.6M. The largest seller was Generation Investment Management, exiting entirely with an estimated $56.1M sold.
- 266 institutional investors held 10x Genomics (TXG) as of Q3 2024, up from 261 in Q2 2024.
- Funds reported $2.36B of 10x Genomics stock for Q3 2024, up 15% quarter-over-quarter.
- 57 funds opened new 10x Genomics positions in Q3 2024 and 49 closed out, a net change of +8 holders.
- The largest 10x Genomics buyer in Q3 2024 was Citadel Advisors, an estimated $50.6M added.
- The largest 10x Genomics seller in Q3 2024 was Generation Investment Management, an estimated $56.1M sold.
Based on aggregated 13F filings for Q3 2024.